Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI) -- Ignore unavailable to you. Want to Upgrade?

To: Wesley Turnblot who wrote (164)	3/19/1998 4:52:00 PM
From: Frank Stein	Read Replies (1) \| Respond to of 579

Wesley: My suspicion is that the Ach deficit in AD is merely a by-product of the disease...and i agree wholeheartedly with you that AD research efforts could be better spent elsewhere.... Could you elaborate on your comment about ACh being downstream of more worthy candidates for AD prevention/intervention.... Do you think, as i do, that Ach is a very far removed by-product of the disease process...That a "worthy candidate" functions in a pathway of some sort....that this putative pathway bifurcates downstream of this "worthy Candidate"....one branch leading to dementia...the other branch exerting an effect on Ach (thereby relegating Ach deficits to a mere by-product of the disease).... Or do you think that Ach functions downstream of a "worthy candidate" in a pathway directly responsible for AD ....in this case...Ach would play a causative role... As far as not investing "time nor money into research towards pharmacological interventions aimed at ACh"....let's not throw out the baby with the bathwater.....Sibia's story is ach and AD....this is on shaky ground...this is not to say that their molecules targeting the Ach system are of no value....The biology of Ach and Ach receptors is fascinating...i would suggest that these compounds may have important Non-AD applications... Frank